Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine.The past five years have resembled a boom-and-bust cycle for the stock as a surge in demand for its vaccine made it a red-hot buy. And now, with the public less concerned about COVID, its share price has gone over a cliff. In just 12 months, its stock is down 65%.One way Moderna has been trying to appease investors and reduce its losses is by cutting costs. And that appears to be working, with the company recently reporting quarterly results showing a sizable decline in expenses. Can leaner, more efficient operations help lure back investors and make this a good healthcare stock to buy again?Continue reading
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine.
The past five years have resembled a boom-and-bust cycle for the stock as a surge in demand for its vaccine made it a red-hot buy. And now, with the public less concerned about COVID, its share price has gone over a cliff. In just 12 months, its stock is down 65%.
One way Moderna has been trying to appease investors and reduce its losses is by cutting costs. And that appears to be working, with the company recently reporting quarterly results showing a sizable decline in expenses. Can leaner, more efficient operations help lure back investors and make this a good healthcare stock to buy again?
